Sign in

    J. Eric Evans

    Chief Executive Officer (CEO) at Surgery Partners Inc
    Board
    Since January 2020
    Age
    47 years
    Education
    Earned a bachelor's degree in Industrial Management from Purdue University and an MBA from Harvard Business School.
    Tenure
    Joined SGRY in April 2019 as Executive Vice President and Chief Operating Officer and was promoted to Chief Executive Officer in January 2020.

    Also at Surgery Partners Inc

    DB
    Danielle Burkhalter
    Executive Vice President and Chief Human Resources Officer
    DTD
    David T. Doherty
    Executive Vice President and Chief Financial Officer
    HRB
    Harrison R. Bane
    President of the National Group

    About

    J. Eric Evans is the Chief Executive Officer and a director at SGRY, with a diverse background in healthcare management and hospital operations.

    He joined the company in April 2019 as Executive Vice President and Chief Operating Officer, later being promoted to CEO in January 2020, underscoring a swift transition to the top leadership role.

    He has built a robust career in the healthcare sector, holding prior leadership positions at Tenet Healthcare Corporation, where he served as President of Hospital Operations and CEO for regional divisions.

    Academically, he earned a bachelor's degree in Industrial Management from Purdue University and an MBA from Harvard Business School, laying a strong foundation for his executive career.

    $SGRY Performance Under J. Eric Evans

    Past Roles

    OrganizationRoleDate RangeDetails
    Surgery Partners Executive Vice President and Chief Operating Officer April 2019 – January 2020 Held prior to becoming CEO
    Tenet Healthcare Corporation President of Hospital Operations March 2016 – 2018 N/A
    Tenet Healthcare Corporation Chief Executive Officer of former Texas region April 2015 – March 2016 N/A
    The Hospitals of Providence in El Paso Market Chief Executive Officer September 2012 – April 2015 N/A

    External Roles

    OrganizationRoleDate RangeDetails
    Teladoc Health Director Since September 2023 N/A
    QuVa Pharma Director Since March 2022 N/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Salary$1,050,000 AnnualFixed base salary for 2024.
    Restricted Stock Award$1,760,000 in fair value; 56,446 shares Vesting on 1st, 2nd, & 3rd anniversariesGrant Date: Feb 28, 2024. One-third vests each anniversary.
    Non-Equity Incentive Plan Compensation$300,000 AnnualTarget of 120% of base; Threshold: $315,000; Maximum: $2,520,000.
    Change in Pension Value and NQDC Earnings$(147) As applicableNegative adjustment due to decrease in pension value.
    All Other Compensation$11,350 Accrual basisIncludes Company 401(k) match of $10,350 and other reimbursements of $1,000.
    Option Awards$156,090 realized At exercise16,500 options exercised at a grant price of $11.54; closing price $21.00.
    Unvested Stock AwardsTotal shares: 12,339; 44,634; 56,446; 37,016; 66,950; 84,669 Outstanding as of Dec 31, 2024Market values: $261,217; $944,902; $1,194,962; $783,629; $1,417,332; $1,792,443 respectively.
    Cash Severance$2,310,000 Upon termination eventRepresents 12 months of base salary continuation and target bonus.
    Equity Payout/Acceleration$7,239,223 (Termination) / $2,401,080 (Death/Disability) Event-triggeredPayout based on termination conditions including change in control or death/disability.
    Health Benefits$23,527 Upon termination eventProvided for termination with or without change in control.

    Performance Compensation

    Data from  FY 2024

    Performance Stock Units (PSUs)

    • Performance Metric: Adjusted EBITDA
    • Threshold: $649.1 million by December 31, 2026
    • Target: 100% award earned if Adjusted EBITDA is between $649.1 million and $666.3 million
    • Maximum: Up to 300% of the award if Adjusted EBITDA reaches $683.8 million
    • Adjustment: Award modified ±10% based on Total Stockholder Return (TSR)
    • Grant Date: February 28, 2024
    • Grant Date Fair Value: $2,640,000
    • Grant Date Stock Price: $31.18 per share
    • Vesting Schedule: One-time cliff vesting on the third anniversary of the grant date

    Cash Incentive Award

    MetricThresholdTargetMaximum2024 ActualWeightingPayout
    Adjusted EBITDA$484.5 million $510.0 million $530.4 million $508.2 million 70%Partial
    Net Revenue$2,909.9 million $3,063.0 million $3,185.5 million $3.11 billion 15%Full
    Free Cash Flow$142.5 million $150.0 million $156.0 million Below threshold 15%None
    • Target Bonus Opportunity: $1,260,000 (120% of base salary)
    • Earned Award for 2024: $1,000,000
    • Settlement: A portion of the cash payout was settled in time-based restricted stock awards vesting on the first anniversary
    • Evaluation Period: Fiscal year 2024, with payout determined after year-end